ASMB - NASDAQ
Assembly Biosciences, Inc.
$24.57
+0.33%Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotAssembly Biosciences, Inc. Management Team
Mr. Jason A. Okazaki J.D.
Chief Executive Officer, President & Director
Compensation
$1,129,460
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR
Chief Human Resources Officer
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Compensation
$655,840
Dr. Anuj Gaggar M.D., Ph.D.
Chief Medical Officer
Dr. William E. Delaney IV, Ph.D.
Chief Scientific Officer
Compensation
$767,242
Ms. Jeanette M. Bjorkquist
Executive Director of Accounting & Treasury
Mr. Thomas E. Rollins
Executive Officer
Compensation
$472,550
Amy Figueroa C.F.A.
Investor Relations Consultant
Mr. Shannon Ryan
Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management
Assembly Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $25.19M and sold $8K worth of ASMB shares, resulting in $25.19M of net buying activity.
3 Months
0
0.00
312
8.31K
-8K
-$8K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
1.2M
25.19M
0
0.00
+25.2M
+$25.19M
Top Buyers
Gilead Sciences, Inc.
10 Percent Owner
$24.80M
Ringo William R
Director
$55K
Altig Anthony E
Director
$55K
Houghton Michael
Director
$55K
Consylman Gina
Director
$55K
Top Sellers
Bjorkquist Jeanette M
Officer: Pfo And Pao
$8K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $25.19M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
ASMB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 17, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | December 21, 2023 | January 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 12, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 12, 2022 | May 25, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | June 11, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 04, 2019 | May 17, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 19, 2018 | May 30, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.